Up-Regulated Expression of Pro-Apoptotic Long Noncoding RNA LincRNA-p21 with Enhanced Cell Apoptosis in Lupus Nephritis

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2021 Jan 5

PMID 33396699

Citations 19

Authors

Yi-Cheng Chen

Pin-Yu Kuo

Yu-Chi Chou

Hao-Earn Chong

Yu-Tung Hsieh

Mei-Lin Yang

Chao-Liang Wu

Ai-Li Shiau

Chrong-Reen Wang

Affiliations

Soon will be listed here.

Abstract

Accelerated cell apoptosis with dysregulated long noncoding RNAs is the crucial pathogenesis in lupus nephritis (LN). Pro-apoptotic lincRNA-p21 was studied in LN patients, cell lines with lentivirus-mediated overexpression and CRISPR interference (CRISPRi)-conducted repression, and a mouse model. Clinical samples were from patients and age/sex-matched controls. Expression of lincRNA-p21 and endogenous RNA target miR-181a, were examined in mononuclear and urine cells. Guide RNA sequences targeting lincRNA-p21 were cloned into CRISPRi with dCas9/ Krüppel-associated box (KRAB) domain. LincRNA-p21-silened transfectants were investigated for apoptosis and miR-181a expression. LincRNA-p21-overexpressed cells were evaluated for apoptosis and p53-related down-stream molecules. Balb/C mice were injected with pristane to induce LN and examined for apoptosis and lincRNA-p21. Higher lincRNA-p21 levels were found in LN mononuclear and urine cells, positively correlated with activity. There were lower miR-181a levels in LN mononuclear cells, negatively correlated with activity. Doxorubicin-induced apoptotic cells had up-regulated lincRNA-p21 levels. CRISPRi with dCas9/KARA domain showed efficient repression ability on transcription initiation/elongation. CRISPRi-conducted lincRNA-p21-silenced transfectants displayed reduced apoptosis with up-regulated miR-181a levels, whereas lentivirus-mediated lincRNA-p21-overexpressed cells revealed enhanced apoptosis with up-regulated downstream PUMA/Bax expression. LN mice had glomerular apoptosis with progressive increased lincRNA-p21 levels. Our results demonstrate up-regulated lincRNA-p21 expression in LN, implicating a potential diagnostic marker and therapeutic target.

Citing Articles

Immunology and treatments of fatty liver disease.

Tang S, Wu S, Zhang W, Ma L, Zuo L, Wang H Arch Toxicol. 2024; 99(1):127-152.

PMID: 39692857 DOI: 10.1007/s00204-024-03920-1.

The diagnostic and predictive potential of lncRNA CASC2 targeting miR-155 in systemic lupus erythematosus patients with nephritis complication.

Mohamed N, El-Fattah A, Shaker O, Sayed G Sci Rep. 2024; 14(1):30537.

PMID: 39690146 PMC: 11652638. DOI: 10.1038/s41598-024-81212-5.

The potential of flavonoids to mitigate cellular senescence in cardiovascular disease.

Zheng H, Li T, Hu Z, Zheng Q, Wang J Biogerontology. 2024; 25(6):985-1010.

PMID: 39325277 DOI: 10.1007/s10522-024-10141-7.

Advances in nephroprotection: the therapeutic role of selenium, silver, and gold nanoparticles in renal health.

Karunakar K, Edwin E, Gopalakrishnan M, Cheriyan B, Ramaiyan V, Karthikha V Int Urol Nephrol. 2024; 57(2):479-510.

PMID: 39312019 DOI: 10.1007/s11255-024-04212-4.

A novel support vector machine-based 1-day, single-dose prediction model of genotoxic hepatocarcinogenicity in rats.

Gi M, Suzuki S, Kanki M, Yokohira M, Tsukamoto T, Fujioka M Arch Toxicol. 2024; 98(8):2711-2730.

PMID: 38762666 DOI: 10.1007/s00204-024-03755-w.

References

Yeo N, Chavez A, Lance-Byrne A, Chan Y, Menn D, Milanova D . An enhanced CRISPR repressor for targeted mammalian gene regulation. Nat Methods. 2018; 15(8):611-616. PMC: 6129399. DOI: 10.1038/s41592-018-0048-5. View

Liu Y, Anders H . Lupus nephritis: from pathogenesis to targets for biologic treatment. Nephron Clin Pract. 2014; 128(3-4):224-31. DOI: 10.1159/000368581. View

Yu F, Haas M, Glassock R, Zhao M . Redefining lupus nephritis: clinical implications of pathophysiologic subtypes. Nat Rev Nephrol. 2017; 13(8):483-495. DOI: 10.1038/nrneph.2017.85. View

Lashine Y, Seoudi A, Salah S, Abdelaziz A . Expression signature of microRNA-181-a reveals its crucial role in the pathogenesis of paediatric systemic lupus erythematosus. Clin Exp Rheumatol. 2011; 29(2):351-7. View

Reeves W, Lee P, Weinstein J, Satoh M, Lu L . Induction of autoimmunity by pristane and other naturally occurring hydrocarbons. Trends Immunol. 2009; 30(9):455-64. PMC: 2746238. DOI: 10.1016/j.it.2009.06.003. View

Chen S, Shiau A, Wu C, Wang C . P53-derived hybrid peptides induce apoptosis of synovial fibroblasts in the rheumatoid joint. Oncotarget. 2018; 8(70):115413-115419. PMC: 5777781. DOI: 10.18632/oncotarget.23268. View

Rapicavoli N, Qu K, Zhang J, Mikhail M, Laberge R, Chang H . A mammalian pseudogene lncRNA at the interface of inflammation and anti-inflammatory therapeutics. Elife. 2013; 2:e00762. PMC: 3721235. DOI: 10.7554/eLife.00762. View

Salmena L, Poliseno L, Tay Y, Kats L, Pandolfi P . A ceRNA hypothesis: the Rosetta Stone of a hidden RNA language?. Cell. 2011; 146(3):353-8. PMC: 3235919. DOI: 10.1016/j.cell.2011.07.014. View

Hochberg M . Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997; 40(9):1725. DOI: 10.1002/art.1780400928. View

10.

Li Q, Chau J, Ebert P, Sylvester G, Min H, Liu G . miR-181a is an intrinsic modulator of T cell sensitivity and selection. Cell. 2007; 129(1):147-61. DOI: 10.1016/j.cell.2007.03.008. View

11.

Ballesteros-Tato A, Papillion A . Mechanisms of action of low-dose IL-2 restoration therapies in SLE. Curr Opin Immunol. 2019; 61:39-45. DOI: 10.1016/j.coi.2019.07.003. View

12.

Gilbert L, Horlbeck M, Adamson B, Villalta J, Chen Y, Whitehead E . Genome-Scale CRISPR-Mediated Control of Gene Repression and Activation. Cell. 2014; 159(3):647-61. PMC: 4253859. DOI: 10.1016/j.cell.2014.09.029. View

13.

Zhou T, Benda C, Dunzinger S, Huang Y, Ho J, Yang J . Generation of human induced pluripotent stem cells from urine samples. Nat Protoc. 2012; 7(12):2080-9. DOI: 10.1038/nprot.2012.115. View

14.

Miret C, Molina R, Filella X, Garcia-Carrasco M, Claver G, Ingelmo M . Relationship of p53 with other oncogenes, cytokines and systemic lupus erythematosus activity. Tumour Biol. 2003; 24(4):185-8. DOI: 10.1159/000074428. View

15.

Huarte M, Guttman M, Feldser D, Garber M, Koziol M, Kenzelmann-Broz D . A large intergenic noncoding RNA induced by p53 mediates global gene repression in the p53 response. Cell. 2010; 142(3):409-19. PMC: 2956184. DOI: 10.1016/j.cell.2010.06.040. View

16.

Mistry P, Kaplan M . Cell death in the pathogenesis of systemic lupus erythematosus and lupus nephritis. Clin Immunol. 2016; 185:59-73. PMC: 5299061. DOI: 10.1016/j.clim.2016.08.010. View

17.

Bonomini F, Santos M, Veronese F, Rezzani R . NLRP3 Inflammasome Modulation by Melatonin Supplementation in Chronic Pristane-Induced Lupus Nephritis. Int J Mol Sci. 2019; 20(14). PMC: 6678949. DOI: 10.3390/ijms20143466. View

18.

Cui J, Qiao Q, Guo Y, Zhang Y, Cheng H, He F . Increased apoptosis and expression of FasL, Bax and caspase-3 in human lupus nephritis class II and IV. J Nephrol. 2011; 25(2):255-61. DOI: 10.5301/JN.2011.8451. View

19.

Peng J, Chen S, Wu C, Chong H, Ding Y, Shiau A . Amelioration of Experimental Autoimmune Arthritis Through Targeting of Synovial Fibroblasts by Intraarticular Delivery of MicroRNAs 140-3p and 140-5p. Arthritis Rheumatol. 2015; 68(2):370-81. DOI: 10.1002/art.39446. View

20.

Spurlock 3rd C, Tossberg J, Matlock B, Olsen N, Aune T . Methotrexate inhibits NF-κB activity via long intergenic (noncoding) RNA-p21 induction. Arthritis Rheumatol. 2014; 66(11):2947-57. PMC: 4211976. DOI: 10.1002/art.38805. View